The Migraine Resource Center collects the most up-to-date clinical research to educate readers on the art and science of migraine management.
The monoclonal antibody reduced the mean number of monthly migraine days in a 3-month open-label extension of the phase 3 CONQUER study.
Changes in the volume and connectivity of the amygdala are associated with headache frequency and affective states.
“All you need is a mat,” said Dr. Rohit Bhatia.
Total medical visit costs and total prescription costs are highest among patients with three or more treatment failures.
“These results will be practice changing,” said Dr. Stephen D. Silberstein.
Clinical Topics & News
Dr. Susan Hutchinson discusses how to make informed treatment choices based on the life stage of the woman with migraine.
The drugs could impair brain blood vessels during ischemic events.
STOWE, VT. – The route of administration, the medicine’s tolerability, and the patient’s preferences all must be considered to enable effective...
Insurers should facilitate transitions to new preventive migraine therapies, including anti-CGRP monoclonal antibodies, headache specialists...
STOWE, VT. – Preventive treatment of migraine can reduce disability and decrease the risk of transformation to...
STOWE, VT. – The disorder is associated with greater disability than nonmenstrual migraine and may be harder to...